Role of lymphangiogenesis in epithelial ovarian cancer
Identifieur interne : 003C33 ( Pmc/Checkpoint ); précédent : 003C32; suivant : 003C34Role of lymphangiogenesis in epithelial ovarian cancer
Auteurs : S S Sundar [Royaume-Uni] ; H. Zhang [Royaume-Uni] ; P. Brown [Royaume-Uni] ; S. Manek [Royaume-Uni] ; C. Han [Royaume-Uni] ; K. Kaur [Royaume-Uni] ; M F L. Charnock [Royaume-Uni] ; D. Jackson [Royaume-Uni] ; T S Ganesan [Royaume-Uni]Source :
- British Journal of Cancer [ 0007-0920 ] ; 2006.
Abstract
We investigated the significance of lymphatic count, vascular count and angiogenic growth factors using immunohistochemistry in 108 tumour specimens of epithelial ovarian cancer with antibodies to lymphatic vessel endothelial hyaluronan receptor (LYVE-1), platelet endothelial cell adhesion molecule CD31, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) in epithelial ovarian cancer to understand the pathogenesis of metastasis in ovarian cancer. The effect of prognostic variables on progression-free and overall survival was assessed. On multivariate analysis, bulky residual disease after surgery was the best prognostic indicator (
Url:
DOI: 10.1038/sj.bjc.6603144
PubMed: 16685274
PubMed Central: 2361318
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:2361318Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of lymphangiogenesis in epithelial ovarian cancer</title><author><name sortKey="Sundar, S S" sort="Sundar, S S" uniqKey="Sundar S" first="S S" last="Sundar">S S Sundar</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Ovarian Cancer Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, H" sort="Zhang, H" uniqKey="Zhang H" first="H" last="Zhang">H. Zhang</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Ovarian Cancer Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Brown, P" sort="Brown, P" uniqKey="Brown P" first="P" last="Brown">P. Brown</name><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Department of Cellular Pathology, John Radcliffe Hospital</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Manek, S" sort="Manek, S" uniqKey="Manek S" first="S" last="Manek">S. Manek</name><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Department of Cellular Pathology, John Radcliffe Hospital</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Han, C" sort="Han, C" uniqKey="Han C" first="C" last="Han">C. Han</name><affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Cancer Research UK, Churchill Hospital, Headington</institution> Oxford OX3 7LF,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kaur, K" sort="Kaur, K" uniqKey="Kaur K" first="K" last="Kaur">K. Kaur</name><affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Cancer Research UK, Churchill Hospital, Headington</institution> Oxford OX3 7LF,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Charnock, M F L" sort="Charnock, M F L" uniqKey="Charnock M" first="M F L" last="Charnock">M F L. Charnock</name><affiliation wicri:level="1"><nlm:aff id="aff4"><institution>Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Headington</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Jackson, D" sort="Jackson, D" uniqKey="Jackson D" first="D" last="Jackson">D. Jackson</name><affiliation wicri:level="1"><nlm:aff id="aff5"><institution>MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Ganesan, T S" sort="Ganesan, T S" uniqKey="Ganesan T" first="T S" last="Ganesan">T S Ganesan</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Ovarian Cancer Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">16685274</idno><idno type="pmc">2361318</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361318</idno><idno type="RBID">PMC:2361318</idno><idno type="doi">10.1038/sj.bjc.6603144</idno><date when="2006">2006</date><idno type="wicri:Area/Pmc/Corpus">000109</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000109</idno><idno type="wicri:Area/Pmc/Curation">000109</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000109</idno><idno type="wicri:Area/Pmc/Checkpoint">003C33</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003C33</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Role of lymphangiogenesis in epithelial ovarian cancer</title><author><name sortKey="Sundar, S S" sort="Sundar, S S" uniqKey="Sundar S" first="S S" last="Sundar">S S Sundar</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Ovarian Cancer Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, H" sort="Zhang, H" uniqKey="Zhang H" first="H" last="Zhang">H. Zhang</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Ovarian Cancer Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Brown, P" sort="Brown, P" uniqKey="Brown P" first="P" last="Brown">P. Brown</name><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Department of Cellular Pathology, John Radcliffe Hospital</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Manek, S" sort="Manek, S" uniqKey="Manek S" first="S" last="Manek">S. Manek</name><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Department of Cellular Pathology, John Radcliffe Hospital</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Han, C" sort="Han, C" uniqKey="Han C" first="C" last="Han">C. Han</name><affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Cancer Research UK, Churchill Hospital, Headington</institution> Oxford OX3 7LF,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kaur, K" sort="Kaur, K" uniqKey="Kaur K" first="K" last="Kaur">K. Kaur</name><affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Cancer Research UK, Churchill Hospital, Headington</institution> Oxford OX3 7LF,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Charnock, M F L" sort="Charnock, M F L" uniqKey="Charnock M" first="M F L" last="Charnock">M F L. Charnock</name><affiliation wicri:level="1"><nlm:aff id="aff4"><institution>Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Headington</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Jackson, D" sort="Jackson, D" uniqKey="Jackson D" first="D" last="Jackson">D. Jackson</name><affiliation wicri:level="1"><nlm:aff id="aff5"><institution>MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Ganesan, T S" sort="Ganesan, T S" uniqKey="Ganesan T" first="T S" last="Ganesan">T S Ganesan</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>Ovarian Cancer Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital</institution> Oxford OX3 9DS,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">British Journal of Cancer</title><idno type="ISSN">0007-0920</idno><idno type="eISSN">1532-1827</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>We investigated the significance of lymphatic count, vascular count and angiogenic growth factors using immunohistochemistry in 108 tumour specimens of epithelial ovarian cancer with antibodies to lymphatic vessel endothelial hyaluronan receptor (LYVE-1), platelet endothelial cell adhesion molecule CD31, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) in epithelial ovarian cancer to understand the pathogenesis of metastasis in ovarian cancer. The effect of prognostic variables on progression-free and overall survival was assessed. On multivariate analysis, bulky residual disease after surgery was the best prognostic indicator (<italic>P</italic><0.001) for progression-free and overall survival (<italic>P</italic><0.001). Lymphatic count was statistically significant as a prognostic factor for progression-free (<italic>P</italic>=0.05) and overall survival (<italic>P</italic>=0.04). However, lymphatic count did not impact on survival curves. No correlation was found between lymphatic count and age, histological subtype, FIGO stage or residual disease. Vascular count, VEGF or TP expressions were not significant in either analysis. Lymphatic spread may be significant in aiding metastases in ovarian cancer but requires other biological factors to act in conjunction, as it does not have clearcut prognostic significance. Dissemination of ovarian cancer does not occur primarily through vascular or lymphatic routes but may occur through direct intraperitoneal spread of disease.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<pmc-comment> Original-type: oa</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16685274</article-id><article-id pub-id-type="pmc">2361318</article-id><article-id pub-id-type="pii">6603144</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6603144</article-id><article-categories><subj-group subj-group-type="heading"><subject>Molecular Diagnostics</subject></subj-group></article-categories><title-group><article-title>Role of lymphangiogenesis in epithelial ovarian cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sundar</surname><given-names>S S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Manek</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kaur</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Charnock</surname><given-names>M F L</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Jackson</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ganesan</surname><given-names>T S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="author-notes" rid="note1">6</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Ovarian Cancer Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital</institution> Oxford OX3 9DS,<country>UK</country></aff><aff id="aff2"><label>2</label><institution>Department of Cellular Pathology, John Radcliffe Hospital</institution> Oxford OX3 9DS,<country>UK</country></aff><aff id="aff3"><label>3</label><institution>Cancer Research UK, Churchill Hospital, Headington</institution> Oxford OX3 7LF,<country>UK</country></aff><aff id="aff4"><label>4</label><institution>Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Headington</institution> Oxford OX3 9DS,<country>UK</country></aff><aff id="aff5"><label>5</label><institution>MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington</institution> Oxford OX3 9DS,<country>UK</country></aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xlink:href="mailto:tsganesan@aims.amrita.edu">tsganesan@aims.amrita.edu</email></corresp><fn fn-type="present-address" id="note1"><label>6</label><p>Current address: Cancer Institute and Institute of Molecular Medicine, Amrita Institute of Medical Sciences, Elamakkara P.O. Kochi, Kerala, India, 682026, E-mail: <email xlink:href="mailto:tsganesan@aims.amrita.edu">tsganesan@aims.amrita.edu</email></p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>05</month><year>2006</year></pub-date><pub-date pub-type="collection"><day>30</day><month>05</month><year>2006</year></pub-date><pub-date pub-type="ppub"><day>05</day><month>06</month><year>2006</year></pub-date><volume>94</volume><issue>11</issue><fpage>1650</fpage><lpage>1657</lpage><history><date date-type="received"><day>31</day><month>10</month><year>2005</year></date><date date-type="rev-recd"><day>03</day><month>04</month><year>2006</year></date><date date-type="accepted"><day>05</day><month>04</month><year>2006</year></date></history><copyright-statement>Copyright 2006, Cancer Research UK</copyright-statement><copyright-year>2006</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>We investigated the significance of lymphatic count, vascular count and angiogenic growth factors using immunohistochemistry in 108 tumour specimens of epithelial ovarian cancer with antibodies to lymphatic vessel endothelial hyaluronan receptor (LYVE-1), platelet endothelial cell adhesion molecule CD31, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) in epithelial ovarian cancer to understand the pathogenesis of metastasis in ovarian cancer. The effect of prognostic variables on progression-free and overall survival was assessed. On multivariate analysis, bulky residual disease after surgery was the best prognostic indicator (<italic>P</italic><0.001) for progression-free and overall survival (<italic>P</italic><0.001). Lymphatic count was statistically significant as a prognostic factor for progression-free (<italic>P</italic>=0.05) and overall survival (<italic>P</italic>=0.04). However, lymphatic count did not impact on survival curves. No correlation was found between lymphatic count and age, histological subtype, FIGO stage or residual disease. Vascular count, VEGF or TP expressions were not significant in either analysis. Lymphatic spread may be significant in aiding metastases in ovarian cancer but requires other biological factors to act in conjunction, as it does not have clearcut prognostic significance. Dissemination of ovarian cancer does not occur primarily through vascular or lymphatic routes but may occur through direct intraperitoneal spread of disease.</p></abstract><kwd-group><kwd>lymphatic density</kwd><kwd>vascular density</kwd><kwd>ovarian carcinoma</kwd><kwd>angiogenesis</kwd><kwd>lymphangiogenesis</kwd></kwd-group></article-meta></front><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Immunostaining of normal ovary and epithelial ovarian cancer with antibodies. Perifollicular lymphatics in normal ovary at × 10 and × 20 magnification (<bold>A</bold> and <bold>B</bold>). Lymphatic vessels adjacent to tumour at × 10, × 20 and × 40 (<bold>C</bold>–<bold>E</bold>). Blood vessels containing RBC are not stained with LYVE-1 (marked with red arrow). Blood vessels in tumour at × 20 (<bold>F</bold>). Vascular endothelial growth factor staining of tumour epithelium at × 20 (VEGF) (<bold>G</bold>). Epithelial staining of tumour (TP) at × 20 (<bold>H</bold>). Arrowheads identify vessels and T marks tumour.</p></caption><graphic mime-subtype="jpeg" xlink:href="94-6603144f1"></graphic></fig><fig id="fig2"><label>Figure 2</label><caption><p>Kaplan–Meier survival plots of lymphatic vessel density in ovarian cancer as an outcome measure for progression-free (<bold>A</bold>) and overall survival (<bold>B</bold>). Lymphatic vessel counts are denoted as < or >18 as indicated. Number of patients=93.</p></caption><graphic mime-subtype="gif" xlink:href="94-6603144f2"></graphic></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Clinicopathological characteristics of the patients</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Characteristic</bold></th><th align="center" valign="top" charoff="50"><bold>All patients</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Total no.</td><td align="center" valign="top" charoff="50">108</td></tr><tr><td align="left" valign="top" charoff="50">Age</td><td align="center" valign="top" charoff="50">25–88</td></tr><tr><td align="left" valign="top" charoff="50">Median age (years)</td><td align="center" valign="top" charoff="50">63</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Histological type</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Serous</td><td align="center" valign="top" charoff="50">35</td></tr><tr><td align="left" valign="top" charoff="50"> Endometrioid</td><td align="center" valign="top" charoff="50">34</td></tr><tr><td align="left" valign="top" charoff="50"> Clear cell</td><td align="center" valign="top" charoff="50">16</td></tr><tr><td align="left" valign="top" charoff="50"> Mucinous</td><td align="center" valign="top" charoff="50">12</td></tr><tr><td align="left" valign="top" charoff="50"> MMMT<sup>a</sup></td><td align="center" valign="top" charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50"> Mixed epithelial</td><td align="center" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50"> Undifferentiated</td><td align="center" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50"> Primary peritoneal</td><td align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50"> Transitional cell carcinoma</td><td align="center" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50"> Not known</td><td align="center" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Differentiation</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Poor</td><td align="center" valign="top" charoff="50">29</td></tr><tr><td align="left" valign="top" charoff="50"> Moderate–poor</td><td align="center" valign="top" charoff="50">7</td></tr><tr><td align="left" valign="top" charoff="50"> Moderate</td><td align="center" valign="top" charoff="50">49</td></tr><tr><td align="left" valign="top" charoff="50"> Well</td><td align="center" valign="top" charoff="50">20</td></tr><tr><td align="left" valign="top" charoff="50"> Not known</td><td align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>FIGO Stage</italic></td></tr><tr><td align="left" valign="top" charoff="50"> I</td><td align="center" valign="top" charoff="50">32</td></tr><tr><td align="left" valign="top" charoff="50"> II</td><td align="center" valign="top" charoff="50">13</td></tr><tr><td align="left" valign="top" charoff="50"> III</td><td align="center" valign="top" charoff="50">49</td></tr><tr><td align="left" valign="top" charoff="50"> IV</td><td align="center" valign="top" charoff="50">14</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Surgery</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Radical</td><td align="center" valign="top" charoff="50">59</td></tr><tr><td align="left" valign="top" charoff="50"> Debulking</td><td align="center" valign="top" charoff="50">46</td></tr><tr><td align="left" valign="top" charoff="50"> Not known</td><td align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50"> Residual disease</td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Microscopic</td><td align="center" valign="top" charoff="50">53</td></tr><tr><td align="left" valign="top" charoff="50"> ⩽2 cm</td><td align="center" valign="top" charoff="50">26</td></tr><tr><td align="left" valign="top" charoff="50"> >2 cm</td><td align="center" valign="top" charoff="50">25</td></tr><tr><td align="left" valign="top" charoff="50"> Not known</td><td align="center" valign="top" charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Chemo-response</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Complete response</td><td align="center" valign="top" charoff="50">55</td></tr><tr><td align="left" valign="top" charoff="50"> Partial response</td><td align="center" valign="top" charoff="50">10</td></tr><tr><td align="left" valign="top" charoff="50"> Progressive disease</td><td align="center" valign="top" charoff="50">14</td></tr><tr><td align="left" valign="top" charoff="50"> Early death</td><td align="center" valign="top" charoff="50">13</td></tr><tr><td align="left" valign="top" charoff="50"> Not evaluable</td><td align="center" valign="top" charoff="50">8</td></tr><tr><td align="left" valign="top" charoff="50"> Not known</td><td align="center" valign="top" charoff="50">8</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Chemotherapy</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Platinum</td><td align="center" valign="top" charoff="50">61</td></tr><tr><td align="left" valign="top" charoff="50"> Non-platinum</td><td align="center" valign="top" charoff="50">14</td></tr><tr><td align="left" valign="top" charoff="50"> No treatment</td><td align="center" valign="top" charoff="50">33</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label></label><p>FIGO=International Federation of Gynaecology and Obstetrics.</p></fn><fn id="tbfnote2"><label>a</label><p>Denotes malignant mixed Mullerian tumour.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Univariate analysis on the association of the variables with the outcome measures</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="3" align="center" valign="top" charoff="50"><bold>Progression-free survival</bold><hr></hr></th><th colspan="3" align="center" valign="top" charoff="50"><bold>Overall survival</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Variable</bold></th><th align="center" valign="top" charoff="50"><bold>HR</bold></th><th align="center" valign="top" charoff="50"><bold>95% CI</bold></th><th align="center" valign="top" charoff="50"><bold><italic>P</italic>-value</bold></th><th align="center" valign="top" charoff="50"><bold>HR</bold></th><th align="center" valign="top" charoff="50"><bold>95% CI</bold></th><th align="center" valign="top" charoff="50"><bold><italic>P</italic>-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Age</td><td align="center" valign="top" charoff="50">1.03</td><td align="center" valign="top" charoff="50">1.01–1.05</td><td align="center" valign="top" charoff="50">0.01</td><td align="center" valign="top" charoff="50">1.03</td><td align="center" valign="top" charoff="50">1.01–1.05</td><td align="center" valign="top" charoff="50">0.001</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Residual disease</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Microscopic</td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> ⩽2 cm</td><td align="center" valign="top" charoff="50">2.50</td><td align="center" valign="top" charoff="50">1.42–4.40</td><td align="center" valign="top" charoff="50">0.001</td><td align="center" valign="top" charoff="50">2.06</td><td align="center" valign="top" charoff="50">1.20–3.54</td><td align="center" valign="top" charoff="50">0.01</td></tr><tr><td align="left" valign="top" charoff="50"> ⩾2 cm</td><td align="center" valign="top" charoff="50">7.07</td><td align="center" valign="top" charoff="50">3.94–12.67</td><td align="center" valign="top" charoff="50"><0.001</td><td align="center" valign="top" charoff="50">7.94</td><td align="center" valign="top" charoff="50">4.48–14.08</td><td align="center" valign="top" charoff="50"><0.001</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Stage</italic></td></tr><tr><td align="left" valign="top" charoff="50"> I</td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> II</td><td align="center" valign="top" charoff="50">2.14</td><td align="center" valign="top" charoff="50">0.92–4.95</td><td align="center" valign="top" charoff="50">0.08</td><td align="center" valign="top" charoff="50">2.27</td><td align="center" valign="top" charoff="50">1.03–5.04</td><td align="center" valign="top" charoff="50">0.04</td></tr><tr><td align="left" valign="top" charoff="50"> III</td><td align="center" valign="top" charoff="50">3.98</td><td align="center" valign="top" charoff="50">2.16–7.34</td><td align="center" valign="top" charoff="50"><0.001</td><td align="center" valign="top" charoff="50">3.78</td><td align="center" valign="top" charoff="50">2.12–6.74</td><td align="center" valign="top" charoff="50"><0.001</td></tr><tr><td align="left" valign="top" charoff="50"> IV</td><td align="center" valign="top" charoff="50">6.69</td><td align="center" valign="top" charoff="50">2.82–15.86</td><td align="center" valign="top" charoff="50"><0.001</td><td align="center" valign="top" charoff="50">5.33</td><td align="center" valign="top" charoff="50">2.33–12.15</td><td align="center" valign="top" charoff="50"><0.001</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Histology</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Endometrioid</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Clear cell</td><td align="center" valign="top" charoff="50">0.63</td><td align="center" valign="top" charoff="50">0.31–1.34</td><td align="center" valign="top" charoff="50">0.24</td><td align="center" valign="top" charoff="50">0.65</td><td align="center" valign="top" charoff="50">0.31–1.34</td><td align="center" valign="top" charoff="50">0.24</td></tr><tr><td align="left" valign="top" charoff="50"> Mucinous</td><td align="center" valign="top" charoff="50">0.71</td><td align="center" valign="top" charoff="50">0.31–1.65</td><td align="center" valign="top" charoff="50">0.43</td><td align="center" valign="top" charoff="50">0.62</td><td align="center" valign="top" charoff="50">0.28–1.50</td><td align="center" valign="top" charoff="50">0.31</td></tr><tr><td align="left" valign="top" charoff="50"> Serous</td><td align="center" valign="top" charoff="50">0.88</td><td align="center" valign="top" charoff="50">0.51–1.53</td><td align="center" valign="top" charoff="50">0.65</td><td align="center" valign="top" charoff="50">1.13</td><td align="center" valign="top" charoff="50">0.68–1.89</td><td align="center" valign="top" charoff="50">0.63</td></tr><tr><td align="left" valign="top" charoff="50"> Others</td><td align="center" valign="top" charoff="50">1.25</td><td align="center" valign="top" charoff="50">0.54–2.89</td><td align="center" valign="top" charoff="50">0.60</td><td align="center" valign="top" charoff="50">1.35</td><td align="center" valign="top" charoff="50">0.59–3.11</td><td align="center" valign="top" charoff="50">0.48</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Differentiation</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Well</td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Moderate</td><td align="center" valign="top" charoff="50">1.42</td><td align="center" valign="top" charoff="50">0.73–2.73</td><td align="center" valign="top" charoff="50">0.30</td><td align="center" valign="top" charoff="50">1.32</td><td align="center" valign="top" charoff="50">0.72–2.43</td><td align="center" valign="top" charoff="50">0.37</td></tr><tr><td align="left" valign="top" charoff="50"> Moderate–poor</td><td align="center" valign="top" charoff="50">0.77</td><td align="center" valign="top" charoff="50">0.62–5.04</td><td align="center" valign="top" charoff="50">0.29</td><td align="center" valign="top" charoff="50">1.80</td><td align="center" valign="top" charoff="50">0.69–4.69</td><td align="center" valign="top" charoff="50">0.23</td></tr><tr><td align="left" valign="top" charoff="50"> Poor</td><td align="center" valign="top" charoff="50">1.92</td><td align="center" valign="top" charoff="50">0.95–3.87</td><td align="center" valign="top" charoff="50">0.07</td><td align="center" valign="top" charoff="50">1.59</td><td align="center" valign="top" charoff="50">0.81–3.12</td><td align="center" valign="top" charoff="50">0.17</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Lymphatic count</td><td align="center" valign="top" charoff="50">1.01</td><td align="center" valign="top" charoff="50">0.99–1.03</td><td align="center" valign="top" charoff="50">0.30</td><td align="center" valign="top" charoff="50">1.01</td><td align="center" valign="top" charoff="50">0.99–1.03</td><td align="center" valign="top" charoff="50">0.41</td></tr><tr><td align="left" valign="top" charoff="50">Vascular count</td><td align="center" valign="top" charoff="50">0.99</td><td align="center" valign="top" charoff="50">0.95–1.02</td><td align="center" valign="top" charoff="50">0.53</td><td align="center" valign="top" charoff="50">0.98</td><td align="center" valign="top" charoff="50">0.95–1.02</td><td align="center" valign="top" charoff="50">0.34</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>TP</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Stroma</td><td align="center" valign="top" charoff="50">1.00</td><td align="center" valign="top" charoff="50">0.81–1.24</td><td align="center" valign="top" charoff="50">0.96</td><td align="center" valign="top" charoff="50">1.11</td><td align="center" valign="top" charoff="50">0.90–1.38</td><td align="center" valign="top" charoff="50">0.33</td></tr><tr><td align="left" valign="top" charoff="50"> 0/1 <italic>vs</italic> 2 <italic>vs</italic> 3</td><td align="center" valign="top" charoff="50">1.01</td><td align="center" valign="top" charoff="50">0.76–1.35</td><td align="center" valign="top" charoff="50">0.94</td><td align="center" valign="top" charoff="50">1.14</td><td align="center" valign="top" charoff="50">0.85–1.51</td><td align="center" valign="top" charoff="50">0.38</td></tr><tr><td align="left" valign="top" charoff="50"> 0/1/2 <italic>vs</italic> 3</td><td align="center" valign="top" charoff="50">1.24</td><td align="center" valign="top" charoff="50">0.73–2.08</td><td align="center" valign="top" charoff="50">0.43</td><td align="center" valign="top" charoff="50">1.44</td><td align="center" valign="top" charoff="50">0.86–2.40</td><td align="center" valign="top" charoff="50">0.17</td></tr><tr><td align="left" valign="top" charoff="50"> 0/1 <italic>vs</italic> 2/3</td><td align="center" valign="top" charoff="50">0.86</td><td align="center" valign="top" charoff="50">0.53–1.41</td><td align="center" valign="top" charoff="50">0.56</td><td align="center" valign="top" charoff="50">1.06</td><td align="center" valign="top" charoff="50">0.65–1.74</td><td align="center" valign="top" charoff="50">0.81</td></tr><tr><td align="left" valign="top" charoff="50"> Epithelium</td><td align="center" valign="top" charoff="50">1.21</td><td align="center" valign="top" charoff="50">0.73–2.04</td><td align="center" valign="top" charoff="50">0.46</td><td align="center" valign="top" charoff="50">1.07</td><td align="center" valign="top" charoff="50">0.63–1.80</td><td align="center" valign="top" charoff="50">0.80</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>VEGF</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Epithelial</td><td align="center" valign="top" charoff="50">0.97</td><td align="center" valign="top" charoff="50">0.79–1.81</td><td align="center" valign="top" charoff="50">0.74</td><td align="center" valign="top" charoff="50">0.97</td><td align="center" valign="top" charoff="50">0.80–1.19</td><td align="center" valign="top" charoff="50">0.79</td></tr><tr><td align="left" valign="top" charoff="50"> Macrophage</td><td align="center" valign="top" charoff="50">1.01</td><td align="center" valign="top" charoff="50">0.84–1.23</td><td align="center" valign="top" charoff="50">0.89</td><td align="center" valign="top" charoff="50">1.02</td><td align="center" valign="top" charoff="50">0.85–1.24</td><td align="center" valign="top" charoff="50">0.81</td></tr><tr><td align="left" valign="top" charoff="50"> Stromal</td><td align="center" valign="top" charoff="50">1.01</td><td align="center" valign="top" charoff="50">0.80–1.28</td><td align="center" valign="top" charoff="50">0.94</td><td align="center" valign="top" charoff="50">0.99</td><td align="center" valign="top" charoff="50">0.78–1.26</td><td align="center" valign="top" charoff="50">0.94</td></tr><tr><td align="left" valign="top" charoff="50"> Vascular</td><td align="center" valign="top" charoff="50">0.98</td><td align="center" valign="top" charoff="50">0.80–1.20</td><td align="center" valign="top" charoff="50">0.83</td><td align="center" valign="top" charoff="50">0.97</td><td align="center" valign="top" charoff="50">0.79–1.19</td><td align="center" valign="top" charoff="50">0.80</td></tr><tr><td align="left" valign="top" charoff="50">VEGF(0–3,4–7,8–12)</td><td align="center" valign="top" charoff="50">1.05</td><td align="center" valign="top" charoff="50">0.73–1.51</td><td align="center" valign="top" charoff="50">0.79</td><td align="center" valign="top" charoff="50">1.07</td><td align="center" valign="top" charoff="50">0.75–1.54</td><td align="center" valign="top" charoff="50">0.71</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote3"><label></label><p>CI=confidence intervals; HR=hazards ratios; TP=thymidine phosphorylase; VEGF=vascular endothelial growth factor.</p></fn><fn id="tbfnote4"><label></label><p>Age was analyzed as a continuous variable. Univariate analysis of TP and VEGF expression was performed by considering the trend in expression.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Multivariate analysis on the association of the variables with outcome measures. 3A Lymphatic count, 3B Vascular count, VEGF and TP as variables</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="3" align="center" valign="top" charoff="50"><bold>Progression-free survival</bold><hr></hr></th><th colspan="3" align="center" valign="top" charoff="50"><bold>Overall survival</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Variable</bold><hr></hr></th><th align="center" valign="top" charoff="50"><bold>HR</bold><hr></hr></th><th align="center" valign="top" charoff="50"><bold>95% CI</bold><hr></hr></th><th align="center" valign="top" charoff="50"><bold><italic>P</italic>-value</bold><hr></hr></th><th align="center" valign="top" charoff="50"><bold>HR</bold><hr></hr></th><th align="center" valign="top" charoff="50"><bold>95% CI</bold><hr></hr></th><th align="center" valign="top" charoff="50"><bold><italic>P</italic>-value</bold><hr></hr></th></tr><tr><th colspan="7" align="left" valign="top" charoff="50">(<bold>A</bold>)</th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Model I</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Age</td><td align="center" valign="top" charoff="50">1.02</td><td align="center" valign="top" charoff="50">1.01–1.05</td><td align="center" valign="top" charoff="50">0.07</td><td align="center" valign="top" charoff="50">1.03</td><td align="center" valign="top" charoff="50">1.01–1.05</td><td align="center" valign="top" charoff="50">0.01</td></tr><tr><td align="left" valign="top" charoff="50"> Lymphatic count</td><td align="center" valign="top" charoff="50">1.02</td><td align="center" valign="top" charoff="50">1.00–1.05</td><td align="center" valign="top" charoff="50">0.05</td><td align="center" valign="top" charoff="50">1.02</td><td align="center" valign="top" charoff="50">1.00–1.04</td><td align="center" valign="top" charoff="50">0.04</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Residual disease</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Microscopic</td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> ⩽2 cm</td><td align="center" valign="top" charoff="50">2.21</td><td align="center" valign="top" charoff="50">1.16–4.20</td><td align="center" valign="top" charoff="50">0.02</td><td align="center" valign="top" charoff="50">1.64</td><td align="center" valign="top" charoff="50">0.088–3.06</td><td align="center" valign="top" charoff="50">0.12</td></tr><tr><td align="left" valign="top" charoff="50"> ⩾2 cm</td><td align="center" valign="top" charoff="50">7.38</td><td align="center" valign="top" charoff="50">3.77–14.46</td><td align="center" valign="top" charoff="50"><0.001</td><td align="center" valign="top" charoff="50">7.43</td><td align="center" valign="top" charoff="50">3.86–14.31</td><td align="center" valign="top" charoff="50"><0.001</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Model II</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Age</td><td align="center" valign="top" charoff="50">1.02</td><td align="center" valign="top" charoff="50">1.00–1.05</td><td align="center" valign="top" charoff="50">0.05</td><td align="center" valign="top" charoff="50">1.03</td><td align="center" valign="top" charoff="50">1.00–1.05</td><td align="center" valign="top" charoff="50">0.02</td></tr><tr><td align="left" valign="top" charoff="50"> Lymphatic count</td><td align="center" valign="top" charoff="50">1.01</td><td align="center" valign="top" charoff="50">0.99–1.03</td><td align="center" valign="top" charoff="50">0.27</td><td align="center" valign="top" charoff="50">1.01</td><td align="center" valign="top" charoff="50">0.99–1.03</td><td align="center" valign="top" charoff="50">0.19</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"><italic>Stage</italic></td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> I</td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> II</td><td align="center" valign="top" charoff="50">1.57</td><td align="center" valign="top" charoff="50">0.63–3.94</td><td align="center" valign="top" charoff="50">0.34</td><td align="center" valign="top" charoff="50">1.62</td><td align="center" valign="top" charoff="50">0.68–3.84</td><td align="center" valign="top" charoff="50">0.27</td></tr><tr><td align="left" valign="top" charoff="50"> III</td><td align="center" valign="top" charoff="50">3.31</td><td align="center" valign="top" charoff="50">1.74–6.31</td><td align="center" valign="top" charoff="50"><0.001</td><td align="center" valign="top" charoff="50">3.05</td><td align="center" valign="top" charoff="50">1.66–5.60</td><td align="center" valign="top" charoff="50"><0.001</td></tr><tr><td align="left" valign="top" charoff="50"> IV</td><td align="center" valign="top" charoff="50">6.26</td><td align="center" valign="top" charoff="50">2.63–14.90</td><td align="center" valign="top" charoff="50"><0.001</td><td align="center" valign="top" charoff="50">4.21</td><td align="center" valign="top" charoff="50">1.88–9.68</td><td align="center" valign="top" charoff="50"><0.001</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">(<bold>B</bold>)</td><td colspan="3" align="center" valign="top" charoff="50"> </td><td colspan="3" align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Model I</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Age</td><td align="center" valign="top" charoff="50">1.02</td><td align="center" valign="top" charoff="50">0.99–1.04</td><td align="center" valign="top" charoff="50">0.11</td><td align="center" valign="top" charoff="50">1.03</td><td align="center" valign="top" charoff="50">1.01–1.05</td><td align="center" valign="top" charoff="50">0.04</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Residual disease</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Microscopic</td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> ⩽2 cm</td><td align="center" valign="top" charoff="50">1.93</td><td align="center" valign="top" charoff="50">1.104– 3.58</td><td align="center" valign="top" charoff="50">0.04</td><td align="center" valign="top" charoff="50">1.79</td><td align="center" valign="top" charoff="50">0.97–3.22</td><td align="center" valign="top" charoff="50">0.06</td></tr><tr><td align="left" valign="top" charoff="50"> ⩾2 cm</td><td align="center" valign="top" charoff="50">6.77</td><td align="center" valign="top" charoff="50">3.58–12.81</td><td align="center" valign="top" charoff="50"><0.001</td><td align="center" valign="top" charoff="50">7.63</td><td align="center" valign="top" charoff="50">4.00–14.58</td><td align="center" valign="top" charoff="50"><0.001</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Vascular count</td><td align="center" valign="top" charoff="50">0.82</td><td align="center" valign="top" charoff="50">0.48–1.40</td><td align="center" valign="top" charoff="50">0.46</td><td align="center" valign="top" charoff="50">0.77</td><td align="center" valign="top" charoff="50">0.44–1.34</td><td align="center" valign="top" charoff="50">0.35</td></tr><tr><td align="left" valign="top" charoff="50"> VEGFe</td><td align="center" valign="top" charoff="50">1.02</td><td align="center" valign="top" charoff="50">0.83–1.25</td><td align="center" valign="top" charoff="50">0.85</td><td align="center" valign="top" charoff="50">1.03</td><td align="center" valign="top" charoff="50">0.84–1.28</td><td align="center" valign="top" charoff="50">0.75</td></tr><tr><td align="left" valign="top" charoff="50"> VEGFm</td><td align="center" valign="top" charoff="50">0.99</td><td align="center" valign="top" charoff="50">0.82–1.20</td><td align="center" valign="top" charoff="50">0.93</td><td align="center" valign="top" charoff="50">0.98</td><td align="center" valign="top" charoff="50">0.81–1.19</td><td align="center" valign="top" charoff="50">0.85</td></tr><tr><td align="left" valign="top" charoff="50"> VEGFs</td><td align="center" valign="top" charoff="50">1.10</td><td align="center" valign="top" charoff="50">0.86–1.41</td><td align="center" valign="top" charoff="50">0.45</td><td align="center" valign="top" charoff="50">1.07</td><td align="center" valign="top" charoff="50">0.83–1.38</td><td align="center" valign="top" charoff="50">0.59</td></tr><tr><td align="left" valign="top" charoff="50"> VEGFv</td><td align="center" valign="top" charoff="50">1.14</td><td align="center" valign="top" charoff="50">0.92–1.42</td><td align="center" valign="top" charoff="50">0.24</td><td align="center" valign="top" charoff="50">1.13</td><td align="center" valign="top" charoff="50">0.91–1.41</td><td align="center" valign="top" charoff="50">0.26</td></tr><tr><td align="left" valign="top" charoff="50"> TPs</td><td align="center" valign="top" charoff="50">0.97</td><td align="center" valign="top" charoff="50">0.79–1.20</td><td align="center" valign="top" charoff="50">0.81</td><td align="center" valign="top" charoff="50">1.07</td><td align="center" valign="top" charoff="50">0.86–1.32</td><td align="center" valign="top" charoff="50">0.55</td></tr><tr><td align="left" valign="top" charoff="50"> TPe</td><td align="center" valign="top" charoff="50">1.36</td><td align="center" valign="top" charoff="50">0.79–2.33</td><td align="center" valign="top" charoff="50">0.27</td><td align="center" valign="top" charoff="50">1.09</td><td align="center" valign="top" charoff="50">0.63–1.88</td><td align="center" valign="top" charoff="50">0.76</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"><italic>Model II</italic></td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Age</td><td align="center" valign="top" charoff="50">1.01</td><td align="center" valign="top" charoff="50">0.99–1.04</td><td align="center" valign="top" charoff="50">0.34</td><td align="center" valign="top" charoff="50">1.02</td><td align="center" valign="top" charoff="50">0.99–1.04</td><td align="center" valign="top" charoff="50">0.16</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Stage</italic></td></tr><tr><td align="left" valign="top" charoff="50"> I</td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">Baseline</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> II</td><td align="center" valign="top" charoff="50">2.07</td><td align="center" valign="top" charoff="50">0.85–5.00</td><td align="center" valign="top" charoff="50">0.11</td><td align="center" valign="top" charoff="50">2.25</td><td align="center" valign="top" charoff="50">0.95–5.32</td><td align="center" valign="top" charoff="50">0.07</td></tr><tr><td align="left" valign="top" charoff="50"> III</td><td align="center" valign="top" charoff="50">3.41</td><td align="center" valign="top" charoff="50">1.77–6.59</td><td align="center" valign="top" charoff="50"><0.001</td><td align="center" valign="top" charoff="50">3.11</td><td align="center" valign="top" charoff="50">1.61–6.04</td><td align="center" valign="top" charoff="50">0.001</td></tr><tr><td align="left" valign="top" charoff="50"> IV</td><td align="center" valign="top" charoff="50">4.44</td><td align="center" valign="top" charoff="50">1.63–12.10</td><td align="center" valign="top" charoff="50"><0.001</td><td align="center" valign="top" charoff="50">4.79</td><td align="center" valign="top" charoff="50">1.74–13.18</td><td align="center" valign="top" charoff="50">0.002</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Vascular count</td><td align="center" valign="top" charoff="50">0.97</td><td align="center" valign="top" charoff="50">0.57–1.65</td><td align="center" valign="top" charoff="50">0.90</td><td align="center" valign="top" charoff="50">0.95</td><td align="center" valign="top" charoff="50">0.56–1.62</td><td align="center" valign="top" charoff="50">0.85</td></tr><tr><td align="left" valign="top" charoff="50"> VEGFe</td><td align="center" valign="top" charoff="50">1.04</td><td align="center" valign="top" charoff="50">0.94–1.29</td><td align="center" valign="top" charoff="50">0.73</td><td align="center" valign="top" charoff="50">1.05</td><td align="center" valign="top" charoff="50">0.84–1.30</td><td align="center" valign="top" charoff="50">0.68</td></tr><tr><td align="left" valign="top" charoff="50"> VEGFm</td><td align="center" valign="top" charoff="50">1.01</td><td align="center" valign="top" charoff="50">0.83–1.23</td><td align="center" valign="top" charoff="50">0.90</td><td align="center" valign="top" charoff="50">1.00</td><td align="center" valign="top" charoff="50">0.82–1.22</td><td align="center" valign="top" charoff="50">1.00</td></tr><tr><td align="left" valign="top" charoff="50"> VEGFs</td><td align="center" valign="top" charoff="50">1.11</td><td align="center" valign="top" charoff="50">0.87–1.41</td><td align="center" valign="top" charoff="50">0.40</td><td align="center" valign="top" charoff="50">1.06</td><td align="center" valign="top" charoff="50">0.83–1.35</td><td align="center" valign="top" charoff="50">1.00</td></tr><tr><td align="left" valign="top" charoff="50"> VEGFv</td><td align="center" valign="top" charoff="50">1.11</td><td align="center" valign="top" charoff="50">0.89–1.39</td><td align="center" valign="top" charoff="50">0.33</td><td align="center" valign="top" charoff="50">1.11</td><td align="center" valign="top" charoff="50">0.89–1.38</td><td align="center" valign="top" charoff="50">0.37</td></tr><tr><td align="left" valign="top" charoff="50"> TPs</td><td align="center" valign="top" charoff="50">1.02</td><td align="center" valign="top" charoff="50">0.82–1.26</td><td align="center" valign="top" charoff="50">0.89</td><td align="center" valign="top" charoff="50">1.12</td><td align="center" valign="top" charoff="50">0.90–1.40</td><td align="center" valign="top" charoff="50">0.29</td></tr><tr><td align="left" valign="top" charoff="50"> TPe</td><td align="center" valign="top" charoff="50">1.28</td><td align="center" valign="top" charoff="50">0.74–2.19</td><td align="center" valign="top" charoff="50">0.38</td><td align="center" valign="top" charoff="50">0.99</td><td align="center" valign="top" charoff="50">0.57–1.70</td><td align="center" valign="top" charoff="50">0.96</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote5"><label></label><p>CI=confidence intervals; HR=hazards ratios; TP=thymidine phosphorylase; VEGF=vascular endothelial growth factor.T</p></fn></table-wrap-foot></table-wrap></floats-wrap></pmc><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Sundar, S S" sort="Sundar, S S" uniqKey="Sundar S" first="S S" last="Sundar">S S Sundar</name></noRegion><name sortKey="Brown, P" sort="Brown, P" uniqKey="Brown P" first="P" last="Brown">P. Brown</name><name sortKey="Charnock, M F L" sort="Charnock, M F L" uniqKey="Charnock M" first="M F L" last="Charnock">M F L. Charnock</name><name sortKey="Ganesan, T S" sort="Ganesan, T S" uniqKey="Ganesan T" first="T S" last="Ganesan">T S Ganesan</name><name sortKey="Han, C" sort="Han, C" uniqKey="Han C" first="C" last="Han">C. Han</name><name sortKey="Jackson, D" sort="Jackson, D" uniqKey="Jackson D" first="D" last="Jackson">D. Jackson</name><name sortKey="Kaur, K" sort="Kaur, K" uniqKey="Kaur K" first="K" last="Kaur">K. Kaur</name><name sortKey="Manek, S" sort="Manek, S" uniqKey="Manek S" first="S" last="Manek">S. Manek</name><name sortKey="Zhang, H" sort="Zhang, H" uniqKey="Zhang H" first="H" last="Zhang">H. Zhang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 003C33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:2361318
|texte= Role of lymphangiogenesis in epithelial ovarian cancer
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:16685274" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |